Hypotestosteronemia is an important factor for the development of hypertension: elevated blood pressure in orchidectomized conscious rats is reversed by different androgens.
5β-dihydrotestosterone
Androgen deficiency
Androgen-regulated blood pressure
Androgens
Antihypertensive response
Hypertension in aging men
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
25
02
2019
accepted:
06
06
2019
pubmed:
17
6
2019
medline:
27
5
2020
entrez:
17
6
2019
Statut:
ppublish
Résumé
Hypotestosteronemia is an aging-associated disease. Little is known about experimental evidence linking androgen deficiency to hypertension. Various androgens are acute vasodilators, both in vitro and in vivo. We aimed to systematically investigate blood pressure (BP) in male normotensive intact or orchidectomized (ORX) Wistar and Wistar-Kyoto rats. Furthermore, we studied the acute antihypertensive responses of testosterone (TES), its precursor (DHEA), or its 5β-reduced metabolite (5β-DHT) in conscious, unrestrained, hypertensive Wistar rats caused by orchidectomy to determine their potency and efficacy. Similarly, the mechanism of their action mediated by nitric oxide (NO) was studied in vivo. BP of ORX rats was evaluated weekly for 18 weeks by tail cuff plethysmography. Subsequently, BP of ORX Wistar rats was measured by chronic indwelling vascular catheters, arterial, and venous catheters were implanted under anesthesia for BP recording and androgen administration, respectively. Then, a dose-response curve of each androgen was performed. Likewise, the dose-response curve of 5β-DHT, the most potent androgen, was repeated in the presence of a nonselective NO synthase inhibitor (L-NAME) or an inhibitor of endothelial NO synthesis (Endothelin-1). ORX rats progressively increased systolic/diastolic BP (167 ± 2.8/141 ± 3.3 mmHg) over 18 weeks. No difference was found between strains. The BP was reduced in a dose-dependent manner caused by i.v. bolus injection of each androgen, with a rank order of potency of: 5β-DHT = DHEA>>TES. Dose-dependent antihypertension induced by 5β-DHT in ORX rats was not abolished in the presence of L-NAME or Endothelin-1. These in vivo experimental findings reveal that hypotestosteronemia is a determining factor for the development of hypertension which is powerfully reduced by androgen administration, and 5β-DHT induces a potent and effective antihypertensive response by a NO-independent mechanism.
Identifiants
pubmed: 31203561
doi: 10.1007/s12020-019-01978-x
pii: 10.1007/s12020-019-01978-x
doi:
Substances chimiques
Androgens
0
Endothelin-1
0
Dihydrotestosterone
08J2K08A3Y
Nitric Oxide
31C4KY9ESH
Testosterone
3XMK78S47O
NG-Nitroarginine Methyl Ester
V55S2QJN2X
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
416-425Références
Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1301-7
pubmed: 20228257
J Steroid Biochem Mol Biol. 2018 Apr;178:65-72
pubmed: 29113921
PLoS One. 2014 Jul 14;9(7):e100409
pubmed: 25019163
Circulation. 1996 Nov 15;94(10):2614-9
pubmed: 8921808
Clin Exp Pharmacol Physiol. 2016 Sep;43(9):825-33
pubmed: 27197589
Nature. 1980 Nov 27;288(5789):373-6
pubmed: 6253831
Exp Clin Endocrinol Diabetes. 2003 Apr;111(2):55-9
pubmed: 12746753
Clin Chim Acta. 2018 Dec;487:90-95
pubmed: 30138621
Exp Clin Endocrinol Diabetes. 2007 Jan;115(1):1-6
pubmed: 17286226
Am J Physiol Regul Integr Comp Physiol. 2011 Jun;300(6):R1288-95
pubmed: 21368267
Physiol Int. 2017 Mar 1;104(1):25-34
pubmed: 28361574
Br J Pharmacol. 2003 Jul;139(6):1235-43
pubmed: 12871844
Int J Obes Relat Metab Disord. 1992 Dec;16(12):991-7
pubmed: 1335979
PLoS One. 2015 Aug 31;10(8):e0137111
pubmed: 26322637
J Hypertens. 2013 Jun;31(6):1106-13
pubmed: 23636018
J Endocrinol Invest. 2009 Oct;32(9):718-23
pubmed: 19535892
J Cardiovasc Pharmacol. 2002 Jun;39(6):814-23
pubmed: 12021575
Clin Sci (Lond). 2013 Oct;125(7):311-8
pubmed: 23746374
J Physiol. 2002 Aug 15;543(Pt 1):365-72
pubmed: 12181306
Vascul Pharmacol. 2012 Mar-Apr;56(3-4):176-82
pubmed: 22326440
Vasa. 2015 Nov;44(6):435-43
pubmed: 26515220
Vasc Health Risk Manag. 2016 Jun 14;12:251-61
pubmed: 27366080
Cell Calcium. 2007 Jul;42(1):11-5
pubmed: 17173968
J Endocrinol. 2013 May 07;217(3):R47-71
pubmed: 23549841
PLoS One. 2019 Mar 21;14(3):e0213351
pubmed: 30897106
Endocrinology. 2008 May;149(5):2517-26
pubmed: 18276759
Biochem Biophys Res Commun. 2004 May 28;318(2):503-6
pubmed: 15120629
PLoS One. 2016 Dec 22;11(12):e0168029
pubmed: 28005919
Am J Physiol Regul Integr Comp Physiol. 2015 Jul 15;309(2):R189-95
pubmed: 25947172
Eur J Pharmacol. 1999 Apr 29;371(2-3):169-78
pubmed: 10357254
Endocrinology. 1973 Jun;92(6):1579-81
pubmed: 4707253
Life Sci. 2008 Oct 10;83(15-16):569-73
pubmed: 18801377
Obes Res. 1993 Jul;1(4):245-51
pubmed: 16350577
J Clin Endocrinol Metab. 2004 Jul;89(7):3313-8
pubmed: 15240608
Nat Clin Pract Urol. 2007 Mar;4(3):161-6
pubmed: 17347661
Am J Epidemiol. 1995 Nov 1;142(9):925-34
pubmed: 7572973
Steroids. 2002 Dec;67(13-14):1021-8
pubmed: 12441187
Br J Pharmacol. 2002 Feb;135(3):735-40
pubmed: 11834621
Atherosclerosis. 2012 Sep;224(1):228-34
pubmed: 22862963
Endocrinology. 2006 Jun;147(6):2675-80
pubmed: 16527846
Pharmacol Rev. 1991 Jun;43(2):109-42
pubmed: 1852778
J Steroid Biochem Mol Biol. 2017 Mar;167:106-114
pubmed: 27888135
Mar Drugs. 2018 May 24;16(6):
pubmed: 29794984
Life Sci. 2007 Sep 1;81(12):993-1002
pubmed: 17804019
Mol Cell Endocrinol. 2010 Mar 25;316(2):180-6
pubmed: 19540307
BMC Cardiovasc Disord. 2013 Apr 18;13:30
pubmed: 23594436
Am J Physiol Heart Circ Physiol. 2001 Oct;281(4):H1720-7
pubmed: 11557563